WO2019192454A9 - 新型小分子免疫激动剂和免疫靶向化合物及其应用 - Google Patents
新型小分子免疫激动剂和免疫靶向化合物及其应用 Download PDFInfo
- Publication number
- WO2019192454A9 WO2019192454A9 PCT/CN2019/080945 CN2019080945W WO2019192454A9 WO 2019192454 A9 WO2019192454 A9 WO 2019192454A9 CN 2019080945 W CN2019080945 W CN 2019080945W WO 2019192454 A9 WO2019192454 A9 WO 2019192454A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- szu
- group
- immune
- pharmaceutically acceptable
- small molecule
- Prior art date
Links
- 0 C1C=*CC=C1 Chemical compound C1C=*CC=C1 0.000 description 8
- JDYWZFPVMGLKGB-UHFFFAOYSA-N COCCOc(nc1[n]2Cc3ccc(CN)cc3)nc(N)c1nc2O Chemical compound COCCOc(nc1[n]2Cc3ccc(CN)cc3)nc(N)c1nc2O JDYWZFPVMGLKGB-UHFFFAOYSA-N 0.000 description 3
- PRMPLUJLGLRHIS-UHFFFAOYSA-N CCCCN1CCN(CCOCCOCCOCCOCCOCCOCCC)CC1 Chemical compound CCCCN1CCN(CCOCCOCCOCCOCCOCCOCCC)CC1 PRMPLUJLGLRHIS-UHFFFAOYSA-N 0.000 description 1
- VYBWTDWSHLFNIC-SNAWJCMRSA-N CN(C)C/C=C/C(NCc1ccc(C[n](c2n3)c(O)nc2c(N)nc3OCCOC)cc1)=O Chemical compound CN(C)C/C=C/C(NCc1ccc(C[n](c2n3)c(O)nc2c(N)nc3OCCOC)cc1)=O VYBWTDWSHLFNIC-SNAWJCMRSA-N 0.000 description 1
- KXQMWISMVFNJEI-UHFFFAOYSA-N COCCOc(nc1[n]2Cc3ccc(CN)cc3)nc(N)c1nc2OC Chemical compound COCCOc(nc1[n]2Cc3ccc(CN)cc3)nc(N)c1nc2OC KXQMWISMVFNJEI-UHFFFAOYSA-N 0.000 description 1
- JYTAWONZCZNIQU-UHFFFAOYSA-N COCCOc(nc1[n]2Cc3ccc(CN=C=S)cc3)nc(N)c1nc2O Chemical compound COCCOc(nc1[n]2Cc3ccc(CN=C=S)cc3)nc(N)c1nc2O JYTAWONZCZNIQU-UHFFFAOYSA-N 0.000 description 1
- CBTLAMBNENDEJN-UHFFFAOYSA-N COCCOc(nc1[n]2Cc3ccc(CNC(C=C)=O)cc3)nc(N)c1nc2O Chemical compound COCCOc(nc1[n]2Cc3ccc(CNC(C=C)=O)cc3)nc(N)c1nc2O CBTLAMBNENDEJN-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N NCCCCC(C(O)=O)N Chemical compound NCCCCC(C(O)=O)N KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the invention relates to a series of small-molecule immune agonists, and immunotargeting compounds obtained by coupling them with a targeting drug, and applications thereof, and belongs to the interdisciplinary field of medicinal chemistry and immunology.
- TLR Toll-like receptor
- ssRNA the natural ligand that activates TLR7 is ssRNA, which plays an important role in defense against ssRNA series virus invasion (Blasius, A.L. & Beutler, B. Intracellular toll-like receptors. Immunity 32, 305-315 (2010)).
- TLR7 can be activated by artificially synthesized small molecule compounds, which induces the body's immune regulation and plays an important role in antiviral and antitumor (Huju Chi, Chunman Li, Flora Sha Zhao, Li Zhang, Tzi Bun Ng, Guangyi Jin Jinand Ou Sha. Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol. 2017 May 31; 8: 304.doi: 10.3389 / fphar.2017.00304).
- TKI tumor necrosinekinase inhibitor
- the object of the present invention is to provide a series of small molecule immune agonists with immune activating effects and applications thereof, and to provide an immune targeting compound obtained by coupling the small molecule immune agonist with a targeting drug and its application.
- a first aspect of the invention relates to a small molecule immunoagonist of formula (I) or an isomer thereof or a pharmaceutically acceptable salt thereof:
- a 1 represents O or C
- a 2 represents a nitro group, an amino group, an isocyanate group, an alkyleneamino group, an alkylene isocyanate group, or a group selected from the group consisting of formula (II) or formula (III):
- R 1 and R 2 each independently represent (CH 2 ) p (NH) q , wherein p is 0, 1 or 2, and q is 0, 1 or 2;
- R 3 represents O or S
- the carbon atom in (CH 2 ) s near the carbonyl group may be substituted by a group selected from the group consisting of -NHBoc, amino, -NHFmoc, Or form a double bond with another carbon atom;
- R 5 represents a hydroxyl group, an alkoxy group, a hydroxylamine group, a vinyl group, or a group selected from the group consisting of:
- R 6 represents an alkyl group or a group selected from:
- the isomer is an isomer or an enantiomer.
- the invention relates to a small molecule immune agonist of formula (I) or an isomer thereof or a pharmaceutically acceptable salt thereof:
- a 1 represents O or C
- a 2 represents a nitro group, an amino group, an isocyanate group, a C 1 -C 6 alkylene amino group, a C 1 -C 6 alkylene isocyanate group, or a group selected from the group consisting of formula (II) or formula (III):
- R 1 and R 2 each independently represent (CH 2 ) p (NH) q , where p is 0 or 1, and q is 0 or 1;
- R 3 represents O or S
- the carbon atom near the carbonyl group may be substituted by a group selected from -NHBoc, amino, -NHFmoc, Or form a double bond with another carbon atom;
- R 5 represents a hydroxyl group, a C 1 -C 6 alkoxy group, a hydroxylamine group, a vinyl group, or a group selected from the group consisting of:
- R 6 represents a C 1 -C 6 alkyl group or a group selected from:
- the invention relates to a small molecule immune agonist of formula (I) or an isomer thereof or a pharmaceutically acceptable salt thereof:
- a 1 represents O or C
- a 2 represents a nitro group, an amino group, an isocyanate group, a methyleneamino group, a methylene isocyanate group, or a group selected from the group consisting of formula (II) or formula (III):
- R 1 and R 2 each independently represent (CH 2 ) p (NH) q , where p is 0 or 1, and q is 0 or 1;
- R 3 represents O or S
- the carbon atom near the carbonyl group may be substituted by a group selected from -NHBoc, amino, -NHFmoc, Or form a double bond with another carbon atom;
- R 5 represents a hydroxyl group, a methoxy group, a hydroxylamine group, a vinyl group, or a group selected from the group consisting of:
- R 6 represents a methyl group or a group selected from:
- the present invention relates to a small molecule immune agonist of formula (I), or an isomer or pharmaceutically acceptable salt thereof, which is a compound selected from the SZU series of compounds (the specific structural formula is shown in Table 1 below) ) Or a pharmaceutically acceptable salt thereof: SZU-104, SZU-105, SZU-107, SZU-108, SZU-109, SZU-110, SZU-111, SZU-112, SZU-113, SZU-115, SZU-118, SZU-120, SZU-127, SZU-128, SZU-129, SZU-131, SZU-132, SZU-133, SZU-134, SZU-135, SZU-136, SZU-137, SZU- 138, SZU-139, SZU-140, SZU-142, SZU-143, SZU-144, SZU-145, SZU-149, SZU
- a second aspect of the present invention relates to an immunotargeting compound or a pharmaceutically acceptable salt thereof, which is a small molecule immune agonist or an addition product thereof formed with a thiol-containing polypeptide such as glutathione and a targeting drug or antibody.
- Valence coupling is formed, and its general formula is expressed as follows:
- TLA represents a small molecule immune agonist or an addition product formed with a thiol-containing polypeptide such as glutathione; Tar represents a targeted drug or antibody; n and m each independently represent a value between 1 and 5; L Represents a connecting chain, which is a linear or branched alkane or a polyethylene glycol chain, and both ends of L are directly covalently connected to TLA and / or Tar or covalently connected to TLA and / or Tar through other groups.
- the small molecule immune agonist comprises the small molecule immune agonist according to the first aspect of the present invention and a compound selected from the following:
- the small molecule immune agonist is selected from the following SZU series compounds (the specific structural formula is shown in Table 1 below) or a pharmaceutically acceptable salt thereof: SZU-102, SZU-104, SZU- 105, SZU-106, SZU-107, SZU-108, SZU-109, SZU-110, SZU-111, SZU-112, SZU-113, SZU-115, SZU-118, SZU-120, SZU-127, SZU-128, SZU-129, SZU-131, SZU-132, SZU-133, SZU-134, SZU-135, SZU-136, SZU-137, SZU-138, SZU-139, SZU-140, SZU- 142, SZU-143, SZU-144, SZU-145, SZU-149, SZU-158, SZU-159, SZU-160,
- SZU series compounds
- TLA is a compound selected from the following (the specific structural formula is shown in Table 3 below): SZU-103-GSH, SZU-114-GSH, SZU-117-GSH, SZU-122-GSH, SZU-127-GSH, SZU-133-GSH, SZU-138-GSH or SZU-144-GSH.
- the Tar is selected from at least one of the following: Dasatinib, Imatinib, Saracatinib, Ponatinib, Nilotinib, Danusertib, AT9283Degrasyn, Bafetinib, kw-2449, nyp-bhg712, dcc-2036, GZD824., GNF-2, PD173955, GNF-5, Bosutinib, Gefitinib, Erlotinib, Sunitinib, Ruxolitinib, Tofacitinib, Lapatinib, Vandetanib, Sorafenib, Sunitinib, Axitinib, Ninededanib, Regorafenib, Pazopanib, Lenvatinib, Cirizinib, Cirizinib Ibrutinib, Niraparib, Palbociclib, B43, KU004, Foreinib, Dasatinib,
- the Tar is selected from at least one of the following: TKI, EGFR inhibitor, KRAS inhibitor, BRAF inhibitor, BTK inhibitor, BRD4 inhibitor, PD-L1 inhibitor, PD- 1 inhibitor, OX40 agonist, PARP inhibitor or CDK4 / 6 inhibitor.
- the other group includes an amide, an alkoxy bond, an alkyl sulfur bond, a substituted amine group, a quaternary amine salt, a heterocyclic ring formed by a cilck reaction, an amino acid group dissociable with a protease, a urea group Or thiourea groups.
- the immune targeting compound or a pharmaceutically acceptable salt thereof is selected from the following SZU series compounds (the specific structural formula is shown in Table 4 below) or a pharmaceutically acceptable salt thereof: SZU-116, SZU-119, SZU-124, SZU-125, SZU-146, SZU-147, SZU-168, SZU-169, SZU-174, SZU-175, SZU-176, SZU-177, SZU-178, SZU- 179, SZU-180, SZU-181, SZU-158-PD-L1, SZU-158-OX40, SZU-158-PD-1 or SZU-136-miRNA21.
- SZU series compounds the specific structural formula is shown in Table 4 below
- the third aspect of the present invention relates to the small molecule immune agonist of formula (I) or its isomer or pharmaceutically acceptable salt according to the first aspect of the present invention, the compounds SZU-101, SZU-103, SZU-114, Use of SZU-117, SZU-122 and SZU-130 (the specific structural formula is shown in Table 2 below) and the immunotargeting compound described in the second aspect of the present invention or a pharmaceutically acceptable salt thereof in the preparation of a medicament involved in immune regulation .
- the fourth aspect of the present invention relates to the small molecule immune agonist of formula (I) according to the first aspect of the present invention or an isomer thereof or a pharmaceutically acceptable salt thereof.
- the compounds SZU-101, SZU-103, SZU-114, SZU-117, SZU-122, and SZU-130 and the immunotargeting compounds or pharmaceutically acceptable salts thereof according to the second aspect of the present invention are used in the preparation of antitumor drugs, antiviral drugs, and drugs that target clearance proteins. use.
- the invention also relates to the use of the compound SZU-136-miRNA21 and its analogs in the preparation of a medicament for immune targeting RNA.
- the compound SZU-136-miRNA21 and its analogs are used as small molecules for immune targeting.
- the medicament can be in various dosage forms, including solid preparations, liquid preparations, complexes formed by the medicaments and various carriers, or crystal water complexes of the medicaments.
- the invention also relates to the use of compounds SZU-179, SZU-180 and SZU-181 in the preparation of medicines against AIDS and hepatitis B.
- compounds SZU-179, SZU-180 and SZU-181 are used as antiviral immune targeting compounds.
- the invention also relates to the use of the compounds SZU-161 and SZU-162 in determining the degree of coupling between a small molecule immune agonist coupled protein drug and a cell.
- compounds SZU-161 and SZU-162 serve as small molecule immune agonists with specific ultraviolet absorption.
- the invention also relates to the use of the compounds SZU-116 and SZU-124 in observing and studying the cellular absorption and in vivo distribution of proteins or targeted drugs, wherein the compounds SZU-116 and SZU-124 are coupled to the protein or targeted drugs.
- Compounds SZU-116 and SZU-124 as compounds with optical tracer properties of small molecule immune agonist color indicator, can be coupled with protein or targeted drug to show cell absorption and distribution of protein or targeted drug in real time .
- the present invention also relates to the use of compounds SZU-114, SZU-117, SZU-122, SZU-127, SZU-133, SZU-138, and SZU-143 in the preparation of a medicament with an immunotargeting dual function, wherein the compound SZU- 114, SZU-117, SZU-122, SZU-127, SZU-133, SZU-138, SZU-143 are conjugated to the targeting drug or antibody.
- the small molecule immune agonist of the present invention itself has an immune activating effect.
- those skilled in the art know that the combined application of TKI and TLR7 immune agonist can cause TKI to antagonize the immune cell activation of TLR7 agonist and inhibit the production of immune-activating cytokines.
- the inventors covalently conjugated the TKI targeting drug and the TLR7 small molecule immune agonist, it was unexpectedly discovered that such covalently coupled compounds not only maintain or enhance the immune activation of small molecule immune agonists, but also improve Antitumor effects of targeted drugs.
- the immune targeting compound obtained by the method of the present invention is of great significance for long-term and highly effective treatment of tumors.
- Some of the small molecule immune agonists in Tables 1 and 2 can form adducts with thiol-containing polypeptides such as glutathione (GSH), which can target glutathione transferase, synergistic chemotherapy drugs, irreversible TKI-targeted drugs and other irreversible targeted drugs to improve the treatment of diseases, eliminate drug resistance, and activate immune effects.
- GSH glutathione
- SZU-117 and glutathione to form SZU-117-GSH adduct the synthesis process is shown in the following formula.
- the exemplified adducts of small molecule immune agonists and GSH are shown in Table 3:
- thiol-containing compounds include, for example, 2-methylamine ethyl mercaptan and SZU-033T Wait.
- the small molecule immune agonists in Tables 1 and 2 and some of the small molecule immune agonists in Table 3 and GSH compounds can be coupled with targeting drugs to obtain bifunctional immune targeting compounds with immune targeting effects.
- the immune targeting compounds are shown in Table 4 below:
- the same method described above is also applicable to the coupling of SZU-144 or SZU-133 with a targeting drug to form an immune-targeting compound.
- the linker can also be a simple linear alkane, or it can be replaced according to various needs.
- Small molecule agonists with carboxyl groups can couple antibodies with addition reactions and coupling reactions to form soluble functional protein polypeptide conjugates, which can form salts due to the dimethylamino group.
- the formation of an ionized positive charge is beneficial to improve the therapeutic effect and water solubility, thereby solving the solubility problem of the coupling product.
- carboxyl-containing small molecule immune agonist can also be coupled with two different targeting drugs to form a dual-targeted immune compound.
- the product formed by a small molecule immune agonist and glutathione can also be coupled with two different targeted drugs to improve the efficacy.
- the targeted drugs can be various TKI drugs and various tumor targeting drugs, or antibodies such as CD3 antibody, PD-1 antibody, OX40 antibody, CD19 antibody, CD20 antibody, HER2 antibody, MUC1 antibody and various tumors. Protein antibodies and pathogenic antibodies.
- the coupling chain can be various alkane chains or alkoxy chains, etc., which can be adjusted according to the needs of dissolution and metabolism optimization.
- the above-mentioned double-coupling immunotargeting compound has the advantage that it can form 2 positive ion amino groups (amino salt -HN + -, -NH + 3 ), high solubility, and the double target can be adjusted and optimized as needed; for example, targeting 1 CD3 antibody or CD122 antibody for T cells, and HER2 inhibitor targeted for tumor cells, which can promote the infiltration of T cells into the tumor microenvironment, enhance the anti-tumor effect, and activate immune TLR7 receptors to generate targeted immune memory .
- Small molecule immune agonist Take SZU-166 as an example, it is a unique isocyanate small molecule immune agonist, which has the advantage of mild and quantitative coupling and addition with amino compounds) Coupling of targeted drug synthesis route five:
- SZU-115 and SZU-160 are new-type small molecule immune agonists with click-reactive groups. Their functions basically include two points. 1) After coupling with macromolecules and biologically active substances, use the click reaction to attach a color indicator. The agent performs optical tracing on the coupling product, for example, after the protein is coupled or the drug is targeted, the cell absorption and distribution of the protein or the drug are observed.
- SZU-115 can also connect antibodies and targeted drugs at the same time, reducing the off-target effect of antibodies, enhancing the effectiveness of targeted drugs, and activating anti-tumor immunity:
- Compound SZU-136 and compound SZU-160 have similar effects and application effects.
- SZU-139 in the present invention is generated by the reaction between SZU-136 and ribose click:
- miRNA21 small molecule immune agonists coupled with small molecule RNA (miRNA), for example, miRNA21 (microRNA21) has an important role in tumorigenesis and development (Cell Death Dis. 2018 Feb 13; 9 (2): 219.doi : 10.1038 / s41419-017-0243-9; Proc Natl Acad Sci US A. 2015 Jun 30; 112 (26): E3355-64.doi: 10.1073 / pnas.1504630112; Cancer Lett.
- miRNA21 small molecule immune agonists coupled with small molecule RNA
- the alkynyl immune agonist can be replaced by SZU-115, and the carboxyl group of SZU-115 can be coupled with Argonaute to form a complex, which interferes with the formation of miRNA and Argonaute complex, and is guided to the endosomes of immune cells under the action of TLR7 agonist, resulting in Immunization and memory:
- the effect of tumors and other diseases has given the dual function of the targeted drug (dual-function targeted drug). This enhanced effect is caused by having immune anti-tumor factors (such as IFN- ⁇ ) and targeting pathogenic targets.
- immune anti-tumor factors such as IFN- ⁇
- the point of inhibiting the synergy of two functions is generated, and the present invention relates to a novel and highly efficient targeted drug with a combination of functions.
- a reasonable effect of the immune targeting compound described in the present invention is to eliminate pathogenic targets (proteins) through the immune pathway, as shown in FIG. 70.
- An immunotargeting compound formed by coupling a small molecule immune agonist with a targeting drug is guided to the pathogenic protein by the targeting drug, causing the targeted cell to die, releasing the pathogenic protein, and then guided by the immune agonist to the antigen-presenting cell (Such as DC, antigen presenting cells), cleavage of pathogenic proteins in cells, resulting in the degradation of these proteins.
- the immune targeting compound formed by the small molecule immune agonist coupled with a targeting drug can overcome drug resistance and improve the therapeutic effect.
- Acid series of small molecule immune agonist lysine-derived compounds SZU-104, SZU-105, SZU-112, SZU-113 are amino acid derivatives with immune agonist activity.
- SZU-161 and SZU-162 as small molecule immune agonists for protein-coupled drugs, have specific UV absorption peaks (342nM), and can be used as a general method for determining the coupling degree of small molecule immune agonist-coupled protein drugs:
- Assay method 1) Determine the light absorption intensity of SZU-161 at ultraviolet 342nM at different concentrations, make a standard curve of concentration and absorbance, and get the concentration-absorbance relationship; 2) determine the coupling protein after coupling protein The absorbance at 342 nM at the concentration can be substituted into the relationship to obtain the relative concentration of SZU-161 in the conjugate.
- SZU-162 has the same application effect.
- immunocytokines represent Cytokine (including IFN- ⁇ , IL-12, IL-6, TNF- ⁇ , etc.), and their concentration can be used to indicate the level of the compound's effect on activating immune cells.
- Figure 1 shows the immune cytokine (IL-6) activation effect of SZU-GSH series compounds.
- FIG. 1 shows the intracellular distribution of fluorescently labeled SZU-116.
- Figure 3 shows the immune cytokine (IFN- ⁇ ) activation effect of SZU-102, 103, 106, 107, 108, 110, 111, 114, 115, 116, 117, 118.
- SZU-101 and R848 are used as standard controls. They are internationally recognized and standard small molecule immune agonists with immune activating effects, the same applies hereinafter.
- Figure 4 shows the immune cytokine (IFN- ⁇ ) activation effect of SZU-143, 144, 146, 147, 149. Where con is the PBS blank control, the same below.
- Figure 5 shows the immune cytokine (IL-12) activation effect of SZU-143, 144, 146, 147, 149.
- Figure 6 shows the immune cytokine (TNF-?) Activation effect of SZU-143, 144, 146, 147, 149.
- Figure 7 shows the immune cytokine (IL-6) activation effect of SZU-143, 144, 146, 147, 149.
- Figure 8 shows the immune cytokine (IFN- ⁇ ) activation effect of SZU-145, 158, 104, 109, 112, 124.
- Figure 9 shows the immune cytokine (IL-12) activation effect of SZU-145, 158, 104, 109, 112, 124.
- Figure 10 shows the immune cytokine (TNF- ⁇ ) activation effect of SZU-145, 158, 104, 109, 112, 124.
- Figure 11 shows the immune cytokine (IL-6) activation effect of SZU-145, 158, 104, 109, 112, 124.
- FIG. 12 shows the activation effect of each immune cytokine of SZU-125.
- Figure 13 shows the immune cytokine (IFN- ⁇ ) activation effect of SZU-105.
- Figure 14 shows the immune cytokine (IL-12) activation effect of SZU-105.
- Figure 15 shows the immune cytokine (IFN- ⁇ ) activation effect of SZU-113.
- Figure 16 shows the immune cytokine (IL-12) activation effect of SZU-113.
- Figure 17 shows the immune cytokine (IL-12) activation effect of SZU-119.
- Figure 18 shows the immune cytokine (IL-6) activation effect of SZU-119.
- FIG. 19 shows the immune cytokine (IFN- ⁇ ) activation effect of SZU-120.
- Figure 20 shows the immune cytokine (IL-6) activation effect of SZU-120.
- 21 to 54 show the activation effects of the immune cytokines of the small molecule immune agonists SZU-122 and 127-142 in the present invention, respectively.
- Figure 55 shows the effect of SZU-102, 119, 125, 146, 147, 169, 174, 175, 168, 176, 177, 179 on activating immune cells to produce IFN- ⁇ .
- Figure 56 shows the effect of SZU-102, 119, 125, 146, 147, 169, 174, 175, 168, 176, 177, 179 on activating immune cells to produce IL-12.
- Figure 57 shows the antitumor (CT26) activity effect of the novel immune targeting compound in vivo: Veh (unadministered control), A (SZU-177), B (SZU-175), C (SZU-174), D ( SZU-147), E (SZU-176).
- CT26 antitumor
- Figure 58 shows the antitumor (B16) activity effect of the novel immune targeting compounds in vivo: Veh (unadministered control), G (PD-L1 antibody), H (SZU-178), I (SZU-158-PD- L1), J (SZU-158-OX40), K (PD-1 antibody), L (SZU-158-PD-1).
- Figure 59 shows that JQ1 inhibits TLR7 agonist activity of SZU-101; SZU-119 maintains the immune cytokine-stimulating activity of TLR7 agonist.
- Figure 60 shows that JQ1 inhibits TLR7 agonist activity of SZU-101; SZU-119 maintains the immunocytokine-stimulating activity of TLR7 agonist.
- Figure 61 shows that SZU-119 maintained the CD274 (PD-L1) inhibitory activity of JQ1 on B16 cells.
- the "control” refers to a blank control.
- Figure 62 shows the effect of SZU-163 and SZU-166 on activating immune cells to produce IFN- ⁇ .
- Figure 63 shows the effect of SZU-180 and SZU-136-miRNA21 on activating IFN- ⁇ production by immune cells.
- FIG. 64 shows the antitumor (4T1) survival rate effect of PD-1 antibody, PD-L1 antibody, OX40 antibody and their SZU-158 conjugates and SZU-178.
- Figure 65 shows the effect of PD-1 antibody, PD-L1 antibody, OX40 antibody and their SZU-158 conjugates and SZU-178 to activate immune cells to produce IFN- ⁇ .
- Figure 66 shows the effect of SZU-181 on activating immune cells to produce IFN- ⁇ .
- FIG. 67 shows the effects of SZU-106, SZU-158, and SZU-160 on activating immune cells to produce IFN- ⁇ , where “control” is a PBS blank control.
- Figure 68 shows the effect of SZU-106, SZU-158, and SZU-160 on activating immune cells to produce IL-6, where "control" is a blank control.
- Figure 69 shows a schematic diagram of the effect of coupling a TLR7 small molecule immune agonist with human miRNA to immuno-target to interfere with the binding of agonist protein and eliminate its related pathogenic effect.
- FIG. 70 is a schematic diagram showing the action of the immune targeting compound in the present invention to eliminate pathogenic targets (proteins) through the immune pathway.
- the synthesis methods of the compounds related to the present invention are exemplified as follows.
- the exemplified synthesis methods can inspire those skilled in the art to realize the synthesis of the novel compounds in the present invention, but the synthesis of the novel compounds in the present invention is not limited to the exemplified synthesis methods.
- the SZU-030T obtained in the previous step was dissolved in 10 mL of anhydrous tetrahydrofuran (THF), 484 mg of triphenylphosphine was added under an ice bath, and the mixture was transferred to room temperature to continue stirring overnight. The progress of the reaction was monitored by LC-MS. After the reaction was completed, 20 mL of water was added, stirring was continued for 30 min, suction filtration was performed under reduced pressure, water was washed twice, and dried to obtain SZU-031T 625 mg. The combined yield in two steps was 79%.
- THF anhydrous tetrahydrofuran
- the preparation method is the same as SZU-116, except that FITC is used instead of SZU-017T to obtain a grass-green semi-solid.
- the combined yield in two steps is 31%.
- ESI-MS: m / z 1199.5 [M + H] + .
- the preparation method is the same as that of SZU-125, except that the PD-1 / PD-L1 inhibitor is replaced by glutaric anhydride, and a white solid is obtained.
- ESI-MS: m / z 459.1 [M + H] + .
- the preparation method is the same as that of SZU-125, except that the PD-1 / PD-L1 inhibitor is replaced by itaconic anhydride, and a white solid is obtained.
- ESI-MS: m / z 457.1 [M + H] + .
- the preparation method is the same as SZU-125, except that the PD-1 / PD-L1 inhibitor is replaced with acetic anhydride, and a white solid is obtained.
- ESI-MS: m / z 387.1 [M + H] + .
- the preparation method is the same as SZU-103-GSH, except that SZU-114 is used instead of SZU-103 to obtain a white solid.
- ESI-MS: m / z 763.3 [M + H] + .
- the preparation method is the same as SZU-103-GSH, except that SZU-117 is used instead of SZU-103 to obtain a white solid.
- ESI-MS: m / z 874.3 [M + H] + .
- the preparation method is the same as SZU-103-GSH, except that SZU-138 is used to replace SZU-103, and 2-dimethylaminoethylthiol is used to replace glutathione. A white solid is obtained.
- ESI-MS: m / z 562.2 [M + H] + .
- the same method can be used to prepare SZU-159, except that SZU138 is replaced with SZU-144 and 2-dimethylaminoethyl mercaptan to react for 24 hours at room temperature to obtain SZU-159.
- the preparation method is the same as SZU-103-GSH, except that SZU-138 is used instead of SZU-103, and SZU-033T is used instead of glutathione. A white solid is obtained.
- ESI-MS: m / z 708.4 [M + H] + .
- the preparation method is the same as SZU-115, except that SZU-032T is used instead of SZU-013T to obtain a white solid.
- ESI-MS: m / z 599.3 [M + H] + .
- Bromine was slowly added dropwise to the acetic acid solution of SZU-151. After stirring overnight, the reaction solution was neutralized with NaHCO 3 . To the obtained viscous compound, for example, a little ethanol is added. A solution of sodium thiosulfate was then added to remove remaining bromine. After suction filtration and drying of the obtained solid, a 10% NaOH solution was added, followed by suction filtration and drying under reduced pressure. Purified liquid chromatography gave bromide.
- a carboxyl compound 155 mg was dissolved in 1.5 mL of DMSO, 79 mg of EDCI and 47 mg of NHS were sequentially added, and after stirring at room temperature for two hours, 50 mg of PEG3 was added to the reaction solution, followed by stirring at room temperature overnight. After the reaction was completed, DMSO was removed by lyophilization and separated by preparative liquid chromatography to obtain 174 mg of a white solid with a yield of 72%.
- ESI-MS: m / z 563.6 [M + H] + .
- SZU-134 was dissolved in DMSO, and equimolar NHS and EDCI were added. After stirring for 10 minutes, equimolar direct violet N (OX40 agonist) was added. The reaction was sealed at room temperature for 3 days. The reactant was added with 20 times water, the precipitated solid was filtered, 2N NaOH was added and stirred at 10 ° C for 30 minutes, and filtered. The filtrate was acidified to pH 1 with 2N hydrochloric acid, and solid product SZU-169 was precipitated. : m / z: [M + 2Na] 1611.64.
- the new immunotargeting compound formed by the SZU-158 conjugated antibody can form a salt due to the dimethylamino group and form a positive ionized charge, which is beneficial to improve the therapeutic effect and water solubility.
- Vemu-1 is a precursor of Vemurafenib and was purchased from WuXi AppTec.
- Vemu-1 was dissolved in DMF, 2 times mole of triethylamine was added, cooled to 0 ° C, 1 times mole of vinylsulfonyl chloride was added, the mixture was slowly warmed to room temperature and stirred for 8 hours, and the mixture was added with 10 times the volume of ice water Stir well for 1 hour, adjust the pH to 8 with saturated Na 2 CO 3 , precipitate a solid, filter, wash twice with water, and dry to obtain Vemu-2.
- 1 g of Vemu-2 was dissolved in 30 mL of DMF, 0.33 g of mercaptoethylamine was added, and the mixture was stirred at room temperature for 12 hours. The solvent was distilled off under reduced pressure to obtain crude Vemu-3. Silica gel column chromatography gave Vemu-3 pure. Product 0.98 g, yield 85%, MS (ESI): m / z: [M + 1] 552.04.
- Osimertinib intermediate was purchased from WuXi AppTec.
- reaction solution was filtered through a filter
- the membrane was filtered and freeze-dried to obtain white solid SZU-178 (that is, SZU-178 coupled with Erlotinib and PD-L1 antibody complex SZU-160-Erlotinib-PD-L1), 12 mg.
- SZU-115-PD-L1-targeting drug that is, the complex formed by SZU-115 coupling PD-L1 antibody and targeting drug
- the method of coupling PD-L1 antibody is the same as that in the preparation of SZU-178, and the click reaction method is the same as that in the preparation of SZU-179 to obtain SZU-180.
- the resulting product can be used to treat AIDS.
- the spleen lymphocytes inoculated in 24-well plates were stimulated with the SZU series of small molecule immune agonists and novel immune targeting compounds of the present invention at different concentrations.
- the 24-well plates were moved into the incubator and the supernatant was gently aspirated after 24 hours of stimulation, that is Samples tested by Elisa. Concentrations and concentration gradients depend on the needs of each measurement sample.
- Coating 10X coating buffer is diluted to 1X and used to dilute the capture antibody. Add 100 ⁇ l of the diluted capture antibody to a 96-well microtiter plate, seal with plastic wrap, and place in a refrigerator at 37 ° C for 2-4 hours or overnight at 4 ° C. Aspirate the liquid from the microtiter plate, wash the plate three times with washing buffer (PBST: PBS solution plus Tween-20 per thousand), and pat dry.
- PBST PBS solution plus Tween-20 per thousand
- Blocking Add 200 ⁇ l of diluted blocking solution to each well, seal with plastic wrap, and block at room temperature for one hour. Wash the plate three times with PBST and pat dry.
- Standard concentrations are: 2000pg / mL, 1000pg / mL, 500pg / mL, 250pg / mL, 125pg / mL, 62.5pg / mL, 31.5pg / mL, 15.75pg / mL, 7.875pg / mL, 3.9375pg / mL , 1.98675 pg / mL, 0 pg / mL.
- TMB 3,3 ', 5,5'-tetramethylbenzidine
- Termination After the color development is completed, 50 ⁇ l of stop solution is added to each well, and the stop solution is 1 mol / L H 2 SO 4 .
- Detection Put the terminated 96-well microplate into a full-wavelength microplate reader and read the absorbance at 450nm. The data was exported, the standard curve was made by software, and the linear regression equation was obtained. Calculate the concentration of immune factors (INF- ⁇ , IL-6, etc.) produced by immune cells. Please refer to the attached drawings for specific experimental results.
- PBS blank control, immune agonist or novel immune targeting compound were administered separately.
- the dosage is determined according to the actual needs (effective and safe dosage principles).
- Each substance is dissolved in an appropriate solvent, and the volume of each administration is 100 ⁇ L; each group is administered by intraperitoneal injection.
- Each group was administered on the 7th, 15th, 22nd, and 29th days after tumor implantation; tumor size was measured regularly. Mice were euthanized when tumors reached 1500 mm 3 or greater than 15% of body weight. See Figures 57, 58 and 64 for tumor suppression and survival results. It can be seen that the treatment group of the novel immune targeting compound in the present invention has a significantly improved antitumor effect.
- the biological activity test method of the novel small molecule immune agonist and the novel immune targeting compound of the present invention is not limited to the above test method, and other related known or recognized activity test methods can also be used.
- the schematic diagram of the activity in the present invention is not limited to the illustrated method. The illustrated method can inspire those skilled in the art to realize the application effect of the novel small molecule immune agonist and novel immune targeting compound in the present invention. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (20)
- 式(I)的小分子免疫激动剂或其异构体或药学上可接受的盐:其中A 1表示O或C;A 2表示硝基、氨基、异氰酸酯基、亚烷基氨基、亚烷基异氰酸酯基或选自式(II)或式(III)的基团:其中R 1和R 2各自独立地表示(CH 2) p(NH) q,其中p为0、1或2,q为0、1或2;R 3表示O或S;R 4表示(CH 2) x(C=O) y(NH) z[(CH 2) 2O] r(CH 2) s(C=C) t,其中x为0至5的整数,y为0、1或2,z为0、1或2,r为0、1、2或3,s为0至5的整数且t为0、1或2,其中当s≠0且t=0时,(CH 2) s中靠近羰基的碳原子可以被选自以下的基团取代:-NHBoc、氨基、-NHFmoc、 或与另一碳原子形成双键;R 5表示羟基、烷氧基、羟胺基、乙烯基或选自以下的基团:其中*表示连接至碳原子的位点;其中排除选自以下的化合物:
- 权利要求1的式(I)的小分子免疫激动剂或其异构体或药学上可接受的盐:其中A 1表示O或C;A 2表示硝基、氨基、异氰酸酯基、C 1-C 6亚烷基氨基、C 1-C 6亚烷基异氰酸酯基或选自式(II)或式(III)的基团:其中R 1和R 2各自独立地表示(CH 2) p(NH) q,其中p为0或1,q为0或1;R 3表示O或S;R 4表示(CH 2) x(C=O) y(NH) z[(CH 2) 2O] r(CH 2) s(C=C) t,其中x为0至5的整数,y为0或1,z为0或1,r为0、1、2或3,s为0至5的整数且t为0或1,其中当s≠0且t=0时,(CH 2) s中靠近羰基的碳原子可以被选自以下的基团取代:-NHBoc、氨基、-NHFmoc、 或与另一碳原子形成双键;R 5表示羟基、C 1-C 6烷氧基、羟胺基、乙烯基或选自以下的基团:其中*表示连接至碳原子的位点;其中排除选自以下的化合物:
- 权利要求2的式(I)的小分子免疫激动剂或其异构体或药学上可接受的盐:其中A 1表示O或C;A 2表示硝基、氨基、异氰酸酯基、亚甲基氨基、亚甲基异氰酸酯基或选自式(II)或式(III)的基团:其中R 1和R 2各自独立地表示(CH 2) p(NH) q,其中p为0或1,q为0或1;R 3表示O或S;R 4表示(CH 2) x(C=O) y(NH) z[(CH 2) 2O] r(CH 2) s(C=C) t,其中x为0至5的整数,y为0或1,z为0或1,r为0、1、2或3,s为0至5的整数且t为0或1,其中当s≠0且t=0时,(CH 2) s中靠近羰基的碳原子可以被选自以下的基团取代:-NHBoc、氨基、-NHFmoc、 或与另一碳原子形成双键;R 5表示羟基、甲氧基、羟胺基、乙烯基或选自以下的基团:其中*表示连接至碳原子的位点;其中排除选自以下的化合物:
- 权利要求3的式(I)的小分子免疫激动剂,或其异构体或药学上可接受的盐,其为选自以下的SZU系列化合物或其药学上可接受的盐:SZU-104、SZU-105、SZU-107、SZU-108、SZU-109、SZU-110、SZU-111、SZU-112、SZU-113、SZU-115、SZU-118、SZU-120、SZU-127、SZU-128、SZU-129、SZU-131、SZU-132、SZU-133、SZU-134、SZU-135、SZU-136、SZU-137、SZU-138、SZU-139、SZU-140、SZU-142、SZU-143、SZU-144、SZU-145、SZU-149、SZU-158、SZU-159、SZU-160、SZU-161、SZU-162、SZU-163、SZU-166或SZU-171。
- 权利要求5的免疫靶向化合物或其药学上可接受的盐,其中所述小分子免疫激动剂为选自以下的SZU系列化合物或其药学上可接受的盐:SZU-102、SZU-104、SZU-105、SZU-106、SZU-107、SZU-108、SZU-109、SZU-110、SZU-111、SZU-112、SZU-113、SZU-115、SZU-118、SZU-120、SZU-127、SZU-128、SZU-129、SZU-131、SZU-132、SZU-133、SZU-134、SZU-135、SZU-136、SZU-137、SZU-138、SZU-139、SZU-140、SZU-142、SZU-143、SZU-144、SZU-145、SZU-149、SZU-158、SZU-159、SZU-160、SZU-161、SZU-162、SZU-163、SZU-166、SZU-171、SZU-101、SZU-103、SZU-114、SZU-117、SZU-122或SZU-130。
- 权利要求5的免疫靶向化合物或其药学上可接受的盐,其中所述TLA为选自以下的化合物:SZU-103-GSH、SZU-114-GSH、SZU-117-GSH、SZU-122-GSH、SZU-127-GSH、SZU-133-GSH、SZU-138-GSH或SZU-144-GSH。
- 权利要求5的免疫靶向化合物或其药学上可接受的盐,其中所述Tar选自以下的至少一种:Dasatinib,Imatinib,Saracatinib,Ponatinib,Nilotinib,Danusertib,AT9283Degrasyn,Bafetinib,kw-2449,nyp-bhg712,dcc-2036,GZD824.,GNF-2,PD173955,GNF-5,Bosutinib,Gefitinib,Erlotinib,Sunitinib,Ruxolitinib,Tofacitinib,Lapatinib,Vandetanib,Sorafenib,Sunitinib,Axitinib,Nintedanib,Regorafenib,Pazopanib,Lenvatinib,Crizotinib,Ceritinib,Cabozantinib,DWF,Afatinib,Ibrutinib,Niraparib,Palbociclib,B43,KU004,Foreinib,KRCA-0008,PF-06439015,PF-06463922,Canerlinib,GSA-10,GW2974,GW583340,W24002,CP-380736,D2667,Mubritinib,PD153035,PD168393,Pelitinib,PF-06459988,PF06672131,PF-6422899,PKI166,ReveromycinA, Tyrphostin 1,tyrphostin23,lyrphostin51,Tyrphostin,AG528,Tyrphostin,AG658,Tyrphostin,AG825,Tyrphostin,AG835,Tyrphostin,AG1478,Tyrphostin,RG13022,Tyrphostin,RG14620,B178,GSK1838705A,PD-161570,PD173074,SU-5402,Roslin2,Picropodophyllotoxin,PQ401,i-ome-tyrphostin,AG538,GNF5837,GW441756,Tyrphostin,AG879,DMPQ,jnj-10198409,PLX647,Trapidil,TyrphostinA9,Tyrhostin,AG370,Lestaurtinib,DMH4,Eldanamvcin,Genistein,Gw2580,HerbimycinA,Lavendustin,CMidostaurin,nvp-bhg712,PD158780,pd-166866,pf-0627334,PP2,RPL,SU11274,SU5614,Symadex,Tyrphostin,AG34,Tyrphostin,AG974,Tyrphostin,AG1007,UNC2881,Honokiol,SU1498,SKLB1002,cp-547632,jk-p3,KRN633,sc-1,ST638,SU 5416,Sulochrin,Tyrphostin,SU1498,rociletinib,Dacomitinib,Tivantinib,Neratinib,Masitinib,Vatalanib,Icotinib,xl-184,osi-930,AB1010,Quizartinib,AZD9291,Tandutinib,HM61713,Brigantinib,Vemurafenib(plx-4032),Semaxanib,AZD2171,Crenolanib,Damnacanthal,Fostamatinib,Motesanib,Radotinib,osi-027,Linsitinib,BIX02189,PF-431396,PND-1186,PF-03814735,PF-431396,sirollmus,temsirolimus,everolimus,deforolimus,Zotarolimus,BEZ235,INK128,Omipalisib,AZD8055,MHY1485,PI-103,KU-0063794,ETP-46464,GDC0349,XL388,WYE-354,WYE-132,GiSK1059615,WAY-600,PF-04691502,wYE-687,PP121,BGT226,AZD2o014,PP242,CH5132799,P529,GDC0980,GDC-0994,XMD82,Ulixertinib,FR180204,SCH772984,Trametinib,PD184352,PD98059,Selumetinib,PD325901,U0126,Pimasertinib,tak-733,AZD8330,Binimetinib,PD318088,SL-327,Refametinib,gdc-0623,Cobimetinib,b1-847325,Adaphostin,GNF2,PPYA,aim-100,ASP 3026,LFM,Toceranib,JQ1,Niraparib,Fuzuopali,palbociclib,ARS-853,ARS-1620,Chlorazol-violet N(直接紫N),miRNA-21,PreS,Zidovudine,Lenvatinib,LY-364947,ARS-1620或Reparixin,EGFR抑制剂,TKI,BRD4抑制剂,KRAS通路相关靶点抑制剂,BRAF抑制剂,BTK抑制剂,PARP抑制剂,PD-L1抑制剂(包括抗体、小分子),PD-1抑制剂(包括抗体、小分子),OX40激动剂(包括 抗体、小分子),CD122抗体,CD3抗体,CD19抑制剂,CD20抑制剂,MUC1抑制剂,MUC16抑制剂,CDK4/6抑制剂,TGF-β抑制剂,CXCR抑制剂,CCL和CXCL趋化因子抑制剂以及miRNA。
- 权利要求9的免疫靶向化合物或其药学上可接受的盐,其中所述Tar选自如下的至少一种:TKI、EGFR抑制剂、KRAS抑制剂、BRAF抑制剂、BTK抑制剂、BRD4抑制剂、PD-L1抑制剂、PD-1抑制剂、OX40激动剂、PARP抑制剂或CDK4/6抑制剂。
- 权利要求5的免疫靶向化合物或其药学上可接受的盐,其中所述其他基团包括酰胺、烷氧键、烷硫键、取代胺基、季胺盐、cilck反应形成的杂环、可用蛋白酶解离的氨基酸基团、脲基团或硫脲基团。
- 权利要求5的免疫靶向化合物或其药学上可接受的盐,其为选自以下的SZU系列化合物或其药学上可接受的盐:SZU-116、SZU-119、SZU-124、SZU-125、SZU-146、SZU-147、SZU-168、SZU-169、SZU-174、SZU-175、SZU-176、SZU-177、SZU-178、SZU-179、SZU-180、SZU-181、SZU-158-PD-L1、SZU-158-OX40、SZU-158-PD-1或SZU-136-miRNA21。
- 权利要求1至4中任一项的式(I)的小分子免疫激动剂或其异构体或药学上可接受的盐,化合物SZU-101、SZU-103、SZU-114、SZU-117、SZU-122和SZU-130以及权利要求5至13中任一项的免疫靶向化合物或其药学上可接受的盐在制备参与免疫调节的药物中的用途。
- 权利要求1至4中任一项的式(I)的小分子免疫激动剂或其异构体或药学上可接受的盐,化合物SZU-101、SZU-103、SZU-114、SZU-117、SZU-122和SZU-130以及权利要求5至13中任一项的免疫靶向化合物或其药学上可接受的盐在制备抗肿瘤药物、抗病毒药物和靶向清除蛋白的药物中的用途。
- 化合物SZU-136-miRNA21及其类似物在制备免疫靶向RNA的药物中 的用途。
- 化合物SZU-179、SZU-180和SZU-181在制备抗艾滋病和抗乙肝的药物中的用途。
- 化合物SZU-161和SZU-162在测定小分子免疫激动剂偶联蛋白药物和细胞的偶联度中的用途。
- 化合物SZU-116和SZU-124在观察研究蛋白或靶向药的细胞吸收和体内分布中的用途,其中化合物SZU-116和SZU-124与蛋白或者靶向药偶联。
- 化合物SZU-114、SZU-117、SZU-122、SZU-127、SZU-133、SZU-138、SZU-143在制备具有免疫靶向双功能的药物中的用途,其中化合物SZU-114、SZU-117、SZU-122、SZU-127、SZU-133、SZU-138、SZU-143与靶向药或抗体偶联。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020553500A JP2021519792A (ja) | 2018-04-03 | 2019-04-02 | 新規低分子免疫アゴニスト、免疫標的化合物、およびそれらの応用 |
US17/044,659 US20230148436A2 (en) | 2018-04-03 | 2019-04-02 | Novel small molecule immune agonists and immune targeting compounds and application thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810289351 | 2018-04-03 | ||
CN201810289351.7 | 2018-04-03 | ||
CN201810331582.X | 2018-04-13 | ||
CN201810331582.XA CN108379591B (zh) | 2018-04-03 | 2018-04-13 | 免疫激动剂靶向化合物的合成及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019192454A1 WO2019192454A1 (zh) | 2019-10-10 |
WO2019192454A9 true WO2019192454A9 (zh) | 2020-01-16 |
Family
ID=63073860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/080945 WO2019192454A1 (zh) | 2018-04-03 | 2019-04-02 | 新型小分子免疫激动剂和免疫靶向化合物及其应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230148436A2 (zh) |
JP (1) | JP2021519792A (zh) |
CN (2) | CN108379591B (zh) |
WO (1) | WO2019192454A1 (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
CN107281483A (zh) * | 2017-04-25 | 2017-10-24 | 深圳大学 | 免疫激动剂和组合物及其应用以及组合物的制备方法 |
CA3089566A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
CN108379591B (zh) * | 2018-04-03 | 2022-03-29 | 深圳大学 | 免疫激动剂靶向化合物的合成及其应用 |
CN109796407A (zh) * | 2018-12-29 | 2019-05-24 | 鼎元(天津)生物医药科技有限公司 | 一种模块化制备化学小分子探针的方法及应用 |
KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
JP2022544234A (ja) | 2019-08-12 | 2022-10-17 | デシフェラ・ファーマシューティカルズ,エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
US20220387417A1 (en) * | 2019-11-11 | 2022-12-08 | Cstone Pharmaceuticals (Suzhou) Co., Ltd. | Pharmaceutical Combination and Use Thereof |
EP4084778B1 (en) | 2019-12-30 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
CN111704614B (zh) * | 2020-04-15 | 2021-10-22 | 深圳大学 | 一种系列免疫激动剂 |
CN111643661A (zh) * | 2020-06-08 | 2020-09-11 | 王竹林 | 新型免疫佐剂、化合物及其应用 |
CN111704603B (zh) * | 2020-06-12 | 2021-10-26 | 四川省人民医院 | 一种抗肿瘤化合物及其应用 |
CN112336852A (zh) * | 2020-10-14 | 2021-02-09 | 深圳大学 | 全细胞疫苗及其制备方法与应用 |
WO2022105836A1 (en) * | 2020-11-19 | 2022-05-27 | Guangzhou Healthquest Pharma Co., Ltd. | Combination therapies for treating cancer |
CN112457297B (zh) * | 2020-11-24 | 2023-04-28 | 福建医科大学 | 一种parp蛋白降解剂及其制备方法与应用 |
CN112957463A (zh) * | 2021-02-22 | 2021-06-15 | 深圳市康居正医药科技有限公司 | 免疫激活型抗体及其应用 |
CN115068625A (zh) * | 2021-03-16 | 2022-09-20 | 中国科学院上海药物研究所 | Pd-l1和tlr7双靶向纳米抗体偶联药物及其在抗肿瘤中的应用 |
WO2022215704A1 (ja) * | 2021-04-09 | 2022-10-13 | 国立大学法人大阪大学 | リガンド-核酸コンジュゲート体 |
CN114163420B (zh) * | 2021-10-26 | 2023-01-24 | 中山大学附属第一医院 | 一种内质网高尔基体靶向小分子、偶联物及其应用 |
WO2023116413A1 (en) * | 2021-12-20 | 2023-06-29 | Versitech Limited | Method of developing a peptide-based vaccine conjugated with 1v209 |
WO2023174312A1 (zh) * | 2022-03-15 | 2023-09-21 | 中国科学院上海药物研究所 | 抗人pd-l1和tlr7双靶向纳米抗体偶联药物及其在抗肿瘤中的应用 |
CN114984014B (zh) * | 2022-06-24 | 2023-09-19 | 中国人民解放军陆军特色医学中心 | 用于治疗脓毒症的抑制剂及其应用 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101230064A (zh) * | 2007-01-22 | 2008-07-30 | 靳广毅 | 9位亚甲基芳基上取代的嘌呤类衍生物 |
PT2510946E (pt) * | 2007-02-07 | 2015-11-23 | Univ California | Conjugados de agonistas sintéticos de tlr e suas utilizações |
CN101239980B (zh) * | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
EP2396328A2 (en) * | 2009-02-11 | 2011-12-21 | The Regents of The University of California | Toll-like receptor modulators and treatment of diseases |
CN103254304A (zh) * | 2012-05-30 | 2013-08-21 | 深圳大学 | 免疫激动剂偶联体、其制备方法及免疫激动剂偶联体在抗肿瘤中的应用 |
CN103566377A (zh) * | 2012-07-18 | 2014-02-12 | 上海博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN105061567B (zh) * | 2012-10-10 | 2021-07-20 | 深圳大学 | 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物 |
CN103467590B (zh) * | 2013-09-02 | 2016-04-13 | 深圳大学 | 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用 |
CN105315281B (zh) * | 2015-11-16 | 2017-04-19 | 深圳大学 | 化合物i和化合物ii及其制备方法和应用 |
CN106267188A (zh) * | 2016-08-15 | 2017-01-04 | 深圳大学 | 小分子免疫激动剂偶联pd‑1抗体的新型抗体及其在抗肿瘤中的应用 |
CN107281483A (zh) * | 2017-04-25 | 2017-10-24 | 深圳大学 | 免疫激动剂和组合物及其应用以及组合物的制备方法 |
CN107281484A (zh) * | 2017-05-31 | 2017-10-24 | 深圳大学 | 用于制备乙肝疫苗的组合物及其制备方法和应用 |
CN108379591B (zh) * | 2018-04-03 | 2022-03-29 | 深圳大学 | 免疫激动剂靶向化合物的合成及其应用 |
-
2018
- 2018-04-13 CN CN201810331582.XA patent/CN108379591B/zh active Active
- 2018-04-13 CN CN202210444543.7A patent/CN115192726A/zh active Pending
-
2019
- 2019-04-02 JP JP2020553500A patent/JP2021519792A/ja active Pending
- 2019-04-02 US US17/044,659 patent/US20230148436A2/en active Pending
- 2019-04-02 WO PCT/CN2019/080945 patent/WO2019192454A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2019192454A1 (zh) | 2019-10-10 |
CN115192726A (zh) | 2022-10-18 |
US20210038605A1 (en) | 2021-02-11 |
JP2021519792A (ja) | 2021-08-12 |
CN108379591B (zh) | 2022-03-29 |
US20230148436A2 (en) | 2023-05-11 |
CN108379591A (zh) | 2018-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019192454A9 (zh) | 新型小分子免疫激动剂和免疫靶向化合物及其应用 | |
AU2021200113A1 (en) | Methods for inhibiting tie2 kinase useful in the treatment of cancer | |
JP7084624B2 (ja) | Cxcr4阻害剤およびその使用 | |
JP5346589B2 (ja) | 水溶性cc−1065類似体及びその接合体 | |
Xi et al. | Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation | |
WO2017092635A1 (zh) | 一种蛋白激酶抑制剂及其制备方法和医药用途 | |
WO2022078259A1 (zh) | 一种氘代的喜树碱衍生物及其抗体药物偶联物 | |
JP6684831B2 (ja) | 化合物 | |
TW201536275A (zh) | 藥物 | |
TWI757726B (zh) | 4(1h)-奎諾酮衍生物及其用途 | |
JP2024516371A (ja) | Egfr変異を有するがんを処置するためのアミノ置換ヘテロ環類 | |
US20220288207A1 (en) | Photo induced control of protein destruction | |
WO2022199547A1 (zh) | 一种7,9-二氢嘌呤衍生物及其制药用途 | |
US20130266590A1 (en) | Dimeric iap inhibitors | |
US20230364243A1 (en) | Cancer-selective target degradation by targeting group caged protacs | |
WO2021154976A1 (en) | Methods of treating brain cancer with panobinostat | |
CN115403583B (zh) | 一种靶向降解fak蛋白的化合物及其用途 | |
CA3227902A1 (en) | Compounds that inhibit pi3k isoform alpha and methods for treating cancer | |
CA3213359A1 (en) | Alk-5 inhibitors and uses thereof | |
WO2013138600A1 (en) | Radioprotector compounds | |
Chen et al. | Fangchinoline derivatives inhibits PI3K signaling in vitro and in vivo in non-small cell lung cancer | |
AU2022407066A1 (en) | Stapled peptide-antibody conjugates (spacs) and uses thereof | |
WO2023107674A2 (en) | Stapled peptide-antibody conjugates (spacs) and uses thereof | |
TW202012384A (zh) | 特定芳基普拉二烯內酯化合物及其使用方法 | |
CN117500803A (zh) | 用于治疗具egfr突变的癌症的氨基取代杂环 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19781756 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020553500 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 26.01.2021 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19781756 Country of ref document: EP Kind code of ref document: A1 |